-

Agilent to Participate at Cowen and Barclays Health Care Conferences

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference and the Barclays Global Health Care Conference. Below are the details:

Cowen 42nd Annual Health Care Conference
Tuesday, March 8, 2022
11:10 a.m. EST / 8:10 a.m. PST

Barclays Global Health Care Conference
Wednesday, March 16, 2022
2:05 p.m. EDT / 11:05 a.m. PDT

Both sessions will be webcast live, and links to join them will be available in the News and Events section of Agilent’s Investor Relations website shortly before the event.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Versions
English
$Cashtags
$A
Hashtags
#agilent

Contacts

INVESTOR CONTACT:
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com

MEDIA CONTACT:
Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

More News From Agilent Technologies Inc.

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC...
Back to Newsroom